235 related articles for article (PubMed ID: 33514922)
1. How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation.
Fuji S; Byrne M; Nagler A; Mohty M; Savani BN
Bone Marrow Transplant; 2021 Jun; 56(6):1248-1256. PubMed ID: 33514922
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient.
Maziarz RT; Devine S; Garrison LP; Agodoa I; Badaracco J; Gitlin M; Perales MA
Transplant Cell Ther; 2023 Oct; 29(10):637.e1-637.e9. PubMed ID: 37364775
[TBL] [Abstract][Full Text] [Related]
4. Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
Pidala J
Cancer Control; 2011 Oct; 18(4):268-76. PubMed ID: 21976245
[TBL] [Abstract][Full Text] [Related]
5. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
[TBL] [Abstract][Full Text] [Related]
6. Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States.
McGuirk J; Divine C; Moon SH; Chandak A; Zhang Z; Papanicolaou GA
Transplant Cell Ther; 2021 Jun; 27(6):505.e1-505.e9. PubMed ID: 33775616
[TBL] [Abstract][Full Text] [Related]
7. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
Aizawa K; Peltier D; Matsuki E; Toubai T
Transfus Apher Sci; 2022 Apr; 61(2):103405. PubMed ID: 35210194
[TBL] [Abstract][Full Text] [Related]
8. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD
PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918
[TBL] [Abstract][Full Text] [Related]
10. The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation.
Gu Z; Xiong Q; Wang L; Wang L; Li F; Hou C; Dou L; Zhu B; Liu D
Cancer; 2022 Apr; 128(7):1402-1410. PubMed ID: 35077579
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
[TBL] [Abstract][Full Text] [Related]
12. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
Du W; Cao X
Front Immunol; 2018; 9():2979. PubMed ID: 30631325
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
[TBL] [Abstract][Full Text] [Related]
15. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
16. Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation.
Gjærde LK; Ostrowski SR; Jørgensen NR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transpl Immunol; 2022 Oct; 74():101650. PubMed ID: 35718288
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality.
Maung K; Ramalingam S; Chaudhry M; Ren Y; Jung SH; Romero K; Corbet K; Chao NJ; Choi T; Diehl AM; Diehl L; Gasparetto C; Horwitz M; Long GD; Lopez RD; Rizzieri DA; Sarantopoulos S; Sullivan KM; Bashir MR; Sung AD
PLoS One; 2020; 15(9):e0238824. PubMed ID: 32915853
[TBL] [Abstract][Full Text] [Related]
18. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
19. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-host disease: why have we not made more progress?
Jaglowski SM; Devine SM
Curr Opin Hematol; 2014 Mar; 21(2):141-7. PubMed ID: 24468835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
